Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

NCT02893488 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: DTG/ABC/3TC FDC DISPERSIBLE TABLET
DRUG: EPZICOM (ABC/3TC)
DRUG: TIVICAY (DTG)

Sponsor

ViiV Healthcare